Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention
New England Journal of Medicine, 09/08/06
Gilles Montalescot, M.D., Ph.D., et al. - In elective PCI, a single intravenous bolus of 0.5 mg of enoxaparin per kilogram is associated with reduced rates of bleeding, and a dose of 0.75 mg per kilogram yields rates similar to those for unfractionated heparin, with more predictable anticoagulation levels. The trial was not large enough to provide a definitive comparison of efficacy in the prevention of ischemic events
| Previous Article | Next Article |
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?
Cancer, 06/04/09
Vitamin D and Melanoma
Annals of Epidemiology , 06/15/09
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
Endocrine-Related Cancer, 06/04/09
Today in Preventive Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation
European Journal of Clinical Investigation, 06/01/09
Valsartan for Prevention of Recurrent Atrial Fibrillation
New England Journal of Medicine, 04/16/09
Vitamin D and Melanoma
Annals of Epidemiology , 06/15/09
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Management of hypertension in acute stroke
Expert Review of Cardiovascular Therapy , 06/12/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
Sponsor
Article Search
Sponsor


See Latest Articles


